NCT05849155 Barriers and Facilitators of Parent-Child Communication in Children With Cancer Predisposition
| NCT ID | NCT05849155 |
| Status | Recruiting |
| Phase | — |
| Sponsor | St. Jude Children's Research Hospital |
| Condition | Genetic Predisposition |
| Study Type | OBSERVATIONAL |
| Enrollment | 125 participants |
| Start Date | 2023-12-12 |
| Primary Completion | 2027-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 125 participants in total. It began in 2023-12-12 with a primary completion date of 2027-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Testing children, adolescents, and young adults (CAYA) for a genetic risk for cancer can help with early prevention and detection of cancers through regular follow-ups and medical care. After receiving genetic test results, CAYA may not accurately understand what their results mean, and parents are often unsure about talking with their CAYA about their genetic risk for cancer. By understanding how parents communicate with their CAYA, the investigators can improve future genetic education to reduce cancer risk. Primary Objectives: * Identify qualities of parent-CAYA (child, adolescent, and young adults) communication about CAYAs' genomic cancer risk, and their association with CAYAs' psychosocial and prevention outcomes. * Examine the association between sociodemographic, cancer-related, and psychosocial factors and parent-CAYA communication regarding CAYAs' genomic risk for cancer. * Identify barriers and facilitators of parent-CAYA communication regarding CAYAs' genomic risk for cancer.
Eligibility Criteria
Inclusion Criteria: * Patient aged 10 to 24 years (inclusive) * Patient underwent germline genetic testing with a Pathogenic/Likely Pathogenic (P/LP) variant in a known cancer predisposition gene that increases risk for developing cancer * P/LP result disclosed to the patient * Patient has a primary caregiver willing to participate * Patient and participating caregiver able to speak and read English Exclusion Criteria: * Patient is only a carrier of a recessive variant that does not alone increase risk for cancer * Inability or unwillingness of patient or participating caregiver or to give informed consent/assent * Participating caregiver is under the age of 18 years * Patient or participating caregiver has evidence of significant cognitive deficits (per medical record) that would interfere with the ability to comprehend study questions * Patient's medical status or condition precludes completion of study (as determined by medical team, patient, or parent)
Contact & Investigator
Katianne Sharp, PhD
PRINCIPAL INVESTIGATOR
St. Jude Children's Research Hospital
Frequently Asked Questions
Who can join the NCT05849155 clinical trial?
This trial is open to participants of all sexes, aged 10 Years or older, up to 24 Years, studying Genetic Predisposition. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05849155 currently recruiting?
Yes, NCT05849155 is actively recruiting participants. Contact the research team at referralinfo@stjude.org for enrollment information.
Where is the NCT05849155 trial being conducted?
This trial is being conducted at Memphis, United States.
Who is sponsoring the NCT05849155 clinical trial?
NCT05849155 is sponsored by St. Jude Children's Research Hospital. The principal investigator is Katianne Sharp, PhD at St. Jude Children's Research Hospital. The trial plans to enroll 125 participants.